tiprankstipranks
Trending News
More News >
Allarity Therapeutics, Inc. (ALLR)
NASDAQ:ALLR
US Market

Allarity Therapeutics (ALLR) AI Stock Analysis

Compare
275 Followers

Top Page

AL

Allarity Therapeutics

(NASDAQ:ALLR)

28Underperform
Allarity Therapeutics' overall stock score is low due to significant financial challenges, including no revenue and consistent operational losses. Technical analysis shows a bearish trend with neutral momentum indicators, while valuation metrics are unfavorable with a negative P/E ratio and no dividend yield. These factors collectively suggest a high-risk investment with limited current appeal.

Allarity Therapeutics (ALLR) vs. S&P 500 (SPY)

Allarity Therapeutics Business Overview & Revenue Model

Company DescriptionAllarity Therapeutics, Inc. (ALLR) is a clinical-stage biopharmaceutical company focused on developing novel oncology therapeutics. The company operates primarily in the biotechnology sector, leveraging its unique Drug Response Predictor (DRP) technology to advance its pipeline of targeted cancer treatments. Allarity is committed to identifying and developing personalized medicines that improve outcomes for patients with unmet medical needs in oncology.
How the Company Makes MoneyAllarity Therapeutics, Inc. generates revenue primarily through strategic partnerships and licensing agreements with other pharmaceutical companies. These collaborations often involve upfront fees, milestone payments, and royalties on future sales of licensed products. The company's revenue model is heavily dependent on advancing its clinical pipeline and securing partnerships for drug development and commercialization. Additionally, Allarity may receive funding through grants and research collaborations aimed at supporting its innovative DRP technology and associated drug development efforts.

Allarity Therapeutics Financial Statement Overview

Summary
Allarity Therapeutics, Inc. faces significant financial challenges with persistent losses and cash flow deficits. While recent equity improvements and low leverage are positive, the company's inability to generate sustainable revenue and positive cash flow presents a risk to its financial health.
Income Statement
20
Very Negative
The company shows a consistent pattern of operating losses with negative EBIT and EBITDA margins over the years, indicating challenges in achieving profitability. However, the gross profit margin for TTM is high at 89.29%, but this is overshadowed by the high net loss. The revenue growth rate is not applicable due to inconsistent revenue figures over the years.
Balance Sheet
25
Negative
The balance sheet reflects instability with a fluctuating stockholders' equity, turning negative in 2023 and back positive in TTM. The debt-to-equity ratio is relatively low in TTM, suggesting low leverage, but past equity deficits highlight financial risks. The equity ratio is reasonable at 63.62% in TTM, indicating some level of asset financing through equity.
Cash Flow
30
Negative
The cash flow statement indicates high operating cash outflows, although recent financing activities helped maintain liquidity. The free cash flow growth rate is negative, highlighting challenges in generating positive cash flows. The operating cash flow to net income ratio is not favorable due to negative net income.
Breakdown
Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
Income StatementTotal Revenue
0.000.000.000.00120.00K
Gross Profit
-37.00K-120.00K-106.00K-86.00K120.00K
EBIT
-17.93M-34.46M-26.56M-9.23M-17.61M
EBITDA
-12.08M-17.24M-25.91M-6.01M-15.58M
Net Income Common Stockholders
-11.90M-16.06M-26.65M-5.07M-14.40M
Balance SheetCash, Cash Equivalents and Short-Term Investments
166.00K2.03M19.55M298.00K1.52M
Total Assets
11.86M14.54M49.63M33.40M31.61M
Total Debt
1.30M3.73M1.09M1.79M963.00K
Net Debt
1.13M1.71M-18.47M1.49M-561.00K
Total Liabilities
14.61M12.65M30.85M6.55M10.70M
Stockholders Equity
-2.75M1.89M18.78M26.85M18.09M
Cash FlowFree Cash Flow
-12.74M-16.84M-15.05M-7.25M-10.12M
Operating Cash Flow
-12.74M-16.82M-15.05M-7.25M-10.11M
Investing Cash Flow
0.00791.00K1.00M-3.00K229.00K
Financing Cash Flow
10.99M-1.31M33.82M6.03M11.20M

Allarity Therapeutics Technical Analysis

Technical Analysis Sentiment
Positive
Last Price1.17
Price Trends
50DMA
0.94
Positive
100DMA
1.01
Positive
200DMA
2.00
Negative
Market Momentum
MACD
0.06
Negative
RSI
58.05
Neutral
STOCH
77.42
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ALLR, the sentiment is Positive. The current price of 1.17 is above the 20-day moving average (MA) of 0.94, above the 50-day MA of 0.94, and below the 200-day MA of 2.00, indicating a neutral trend. The MACD of 0.06 indicates Negative momentum. The RSI at 58.05 is Neutral, neither overbought nor oversold. The STOCH value of 77.42 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ALLR.

Allarity Therapeutics Risk Analysis

Allarity Therapeutics disclosed 87 risk factors in its most recent earnings report. Allarity Therapeutics reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Allarity Therapeutics Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
52
Neutral
$5.28B3.75-42.72%2.86%17.70%2.03%
51
Neutral
$20.34M-31.35%603.12%68.27%
48
Neutral
$19.05M698.040.04%10081.34%
37
Underperform
$16.21M354.78%64.19%
35
Underperform
$16.71M-150.67%-126.54%
32
Underperform
$22.33M-154.54%66.72%
28
Underperform
$19.91M-541.17%99.43%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
ALLR
Allarity Therapeutics
1.11
-28.89
-96.30%
LPCN
Lipocine
3.56
-1.12
-23.93%
EDSA
Edesa Biotech
2.38
-2.25
-48.60%
SLGL
Sol-Gel Technologies
0.73
-0.12
-14.12%
BIVI
BioVie
1.21
-3.69
-75.31%
CLDI
Calidi Biotherapeutics
0.48
-1.49
-75.63%

Allarity Therapeutics Corporate Events

Executive/Board ChangesShareholder Meetings
Allarity Therapeutics Restructures Board of Directors
Neutral
Apr 16, 2025

On April 16, 2025, Allarity Therapeutics, Inc. restructured its Board of Directors to achieve a more balanced membership among its classes by moving Thomas H. Jensen from Class I to Class III. This change was made to ensure continuity in board service, with Mr. Jensen’s term now expiring in 2028. Additionally, the company announced that its 2025 annual meeting of stockholders will be held on June 13, 2025, with a record date set for April 16, 2025. The meeting date was advanced by more than 30 days from the previous year’s anniversary, prompting the company to file a Current Report to inform stockholders and outline the submission deadlines for stockholder proposals and nominations.

Spark’s Take on ALLR Stock

According to Spark, TipRanks’ AI Analyst, ALLR is a Underperform.

Allarity Therapeutics faces substantial financial challenges, with no revenue and consistent operational losses, which weigh heavily on its stock score. Technical indicators provide a neutral outlook without strong trends, and valuation is difficult due to negative earnings. These factors combine to result in a low score, highlighting significant risks for investors.

To see Spark’s full report on ALLR stock, click here.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.